FDA grants priority review to Simeprevir

“This is a very important step bringing simeprevir closer to the market, making this therapy available to hepatitis C patients” comments Charlotte Edenius, EVP Development of Medivir.

Read more

 

Portfolio

Medivir’s portfolio prioritize pharmaceuticals against infectious diseases caused by virus.
View portfolio

Financial information 2013
  • The Interim Report for January-June will be published on 22 August
  • The Interim Report for January-September will be published on 21 November
Simeprevir presented via a webcast

Read more

A fully owned subsidiary

Biophausia Logotyp